NR3C2 and adrenal gland hyperfunction: Non-classical PA, hypercortisolism, and non-classical AME may all potentially respond well to MR antagonists, and therefore, future studies are needed to evaluate the efficacy of early initiation of MR antagonists in the treatment of LRH to formulate evidence-based clinical practice recommendations.